Back to top

Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
September 19, 2017

Read MoreHide Full Article

Clovis Oncology, Inc. (CLVS - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $67.17 to $78.26 in the past one-month time frame.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Clovis Oncology, Inc. Price

A better-ranked stock in the Medical sector is Alexion Pharmaceuticals, Inc. (ALXN - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CLVS going up? Or down? Predict to see what others think: Upor Down

4 Promising Stock Picks to Keep an Eye On

With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor’s Guide to Locking Down Profits to help answer this question.

This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.

Get the new Investing Guide now>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Alexion Pharmaceuticals, Inc. (ALXN) - free report >>

Clovis Oncology, Inc. (CLVS) - free report >>


More from Zacks Tale of the Tape

You May Like